A Pragmatic Randomized Trial Standard of Care Vascular Access Strategies for (Neo)Adjuvant Trastuzumab-based Breast Cancer Treatment OTT 15-06 A Study From the REthinking Clinical Trials Program (REaCT-vascular Access Trastuzumab Study).
In the REaCT-Vascular Access Trastuzumab study (REaCT-VA), the investigator will use a novel
method to allow comparisons of established standard of care vascular access strategies using
the "integrated consent model" as part of a pragmatic clinical trial. The investigator
wishes to address a non-pharmacologic issue regarding standard of care vascular access
devices. Peripherally inserted central catheters (PICC lines) versus subcutaneously
implanted devices (PORTs).
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society